Bristol-Myers Squibb: I See No Catalysts To Break Underperformance [Seeking Alpha]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Seeking Alpha
BMY's pipeline and recent acquisitions are unlikely to offset revenue declines, with new therapies facing intense competition and limited blockbuster potential. Financial fundamentals are deteriorating, with falling revenue, EBITDA margins, and net income, while high debt and weak free cash flow constrain flexibility. I recommend investors avoid BMY for the foreseeable future and only a dividend cut may preserve cash and navigate the challenging outlook. JHVEPhoto/iStock Editorial via Getty Images Introduction Bristol-Myers Squibb ( BMY ) is a company that was blessed with multiple early mega blockbuster therapies: Eliquis, Opdivo, and Revlimid (via Celgene). Sometimes, mega blockbusters are more of a curse than a blessing. They lead to tremendous financial fortune for This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 7
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)Business Wire
- Bristol Myers Squibb (NYSE:BMY) had its "sector perform" rating reaffirmed by analysts at Scotiabank.MarketBeat
- How faster decisions can transform patient care in Canada [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Bristol Myers Squibb (NYSE:BMY) was given a new $65.00 price target on by analysts at Truist Financial Corporation.MarketBeat
BMY
Earnings
- 10/31/25 - Beat
BMY
Sec Filings
- 11/18/25 - Form 8-K
- 11/12/25 - Form CERT
- 11/10/25 - Form 8-A12B
- BMY's page on the SEC website